Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
We hypothesise that patients with SARS-Cov-2 infection are characterized by progressive changes in distribution of distinct lung macrophages populations mediated by influx of circulating monocytes into the lungs . Moreover, we also hypothesise that patients with higher rate of MerTKpos alveolar macrophages in the lung lavage will have the lowest rate of lung complications and the best recovery outcome in terms of clinical outcome and need of assisted ventilation supporting the use of macrophage phenotyping as novel prognostic biomarker in patients with SARS-Cov-2 infection. Finally, the definition of the transcriptomic signature of peripheral blood and tissue-derived myeloid cell subtypes will offer new therapeutic target of this uncurable newly discovered infection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SARS-Cov-2pos pneumonia with moderate/severe lung manifestations with clinical worsening | (PaO2/FiO2<200) |
| |
| SARS-Cov-2pos pneumonia with moderate/severe lung manifestations with clinical improvement | (PaO2/FiO2>200) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Immune-phenotyping of tissue and peripheral blood myeloid compartment | Other | Peripheral blood sampling and bronchoalveolar lavage fluid collection based on the clinical indication at baseline (T0) and peripheral blood sample at the time of clinical worsening/improvement during the follow-up (T1). Moreover, after complete recovery and discharge from the hospital peripheral blood sampling in the outpatient clinical assessment will be performed (T2). BALF and peripheral blood will be processed for immune-phenotyping of the myeloid compartment using single-cell RAN sequencing analysis. |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical improvement as shown by PaO2/FiO2>200 | 28 days |
Not provided
Not provided
Inclusion Criteria:
- Patients with COVID-19 pneumonia
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients hospedalized for Covid-19 pneumonia.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Division of Rheumatology | Recruiting | Rome | Lazio | 00168 | Italy |
Not provided
Not provided
Not provided
Not provided
|
| School of Infection and Immunity | Active, not recruiting | Glasgow | United Kingdom |